Graph AI, an AI-native patient safety startup, has secured $13.3 million in Series A funding led by Insight Partners. The company claims its platform reduces safety case processing time from over three hours to under 10 minutes.
TL;DR
- Graph AI raises $13.3M to expand its AI-driven pharmacovigilance platform, Graph Safety.
- The platform aims to automate manual tasks in drug safety monitoring, reducing processing time and operating costs.
- Graph AI plans to launch a new module for aggregate safety reporting in September.
What happened
Graph AI, founded in 2024, has raised $13.3 million in a Series A funding round led by Insight Partners, with participation from existing investor Bessemer Venture Partners. This follows a $3 million seed round led by Bessemer in October 2025.
The funding will support the startup's expansion across the US and Europe. Graph AI develops Graph Safety, a platform designed to automate parts of pharmacovigilance, the monitoring and management of potential safety problems associated with medicines.
Graph Safety combines AI with predetermined controls, validation layers, and end-to-end audit trails, aiming to trace and review source data and system outputs by people. The startup claims that in live deployments, its software has reduced the time taken to process safety cases from more than three hours to less than 10 minutes, while cutting operating costs by as much as 66%.
Graph AI has brought two modules to market since its seed round: Intake, designed to capture and triage incoming reports of adverse events, and Nucleus, a safety database that automates case processing. A third module, Report, is due to launch in September, and the startup is also working on Signal, a planned module intended to identify emerging safety signals and patterns across cases.
Why it matters
For AI/ML developers, Graph AI's success highlights the growing demand for AI solutions in the pharmaceutical industry, particularly in automating manual and time-consuming tasks. The startup's claims of significant time and cost savings could set a new benchmark for similar platforms.
Startup founders in the AI and healthcare sectors should take note of Graph AI's approach to integrating AI with regulatory compliance and human oversight. The company's focus on traceability and accountability could serve as a model for other startups in the space.
Tech investors may see Graph AI's funding round as an indicator of the potential for AI-driven solutions in pharmacovigilance. The startup's ability to secure significant funding from reputable investors like Insight Partners and Bessemer Venture Partners suggests a strong belief in the market opportunity and the company's technology.
Key facts
- Graph AI raised $13.3 million in Series A funding led by Insight Partners.
- Existing investor Bessemer Venture Partners also participated in the financing.
- The funding will support the startup's expansion across the US and Europe.
- Graph Safety claims to reduce safety case processing time from over three hours to under 10 minutes.
- The platform aims to cut operating costs by as much as 66%.
- Graph AI has brought two modules to market: Intake and Nucleus.
- A third module, Report, is due to launch in September.
- The startup is also working on Signal, a planned module for identifying emerging safety signals.
Context
Graph AI's focus on automating pharmacovigilance comes at a time when pharmaceutical companies are increasingly looking to AI to manage growing case volumes and improve patient safety. The startup's approach to integrating AI with regulatory compliance and human oversight could set a new standard for the industry.
The pharmaceutical industry has traditionally dealt with increasing case volumes by adding staff and processes around older systems. Graph AI's intelligent system aims to take on operational complexity while keeping traceability, accountability, and human oversight at the center.
The startup's claims of significant time and cost savings could have a profound impact on the way pharmaceutical companies manage patient safety. If Graph AI's technology lives up to its promises, it could become a key player in the AI-driven transformation of the pharmaceutical industry.